Letizia Santinelli

Ms. Letizia Santinelli

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2026 in Movement Disorders
Verified
Journal Article
Open access
LSLetizia Santinelli
Letizia Santinelli
NPNeringa Pratuseviciute
Neringa Pratuseviciute
LLLara M. Lange
Lara M. Lange
TKTeresa Kleinz
Teresa Kleinz
NBNorbert Brüggemann
Norbert Brüggemann
MBMax Borsche
Max Borsche

20 October 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DTDavide Tosin
Davide Tosin
FSFelix Seyfried
Felix Seyfried
AHAnnika Hajosch
Annika Hajosch
DSDominik Schlotter
Dominik Schlotter
LSLetizia Santinelli
Letizia Santinelli
Georg Karpel-MasslerGeorg Karpel-Massler
Georg Karpel-Massler
Background/Objectives: Glioblastoma exhibits profound therapy resistance driven in part by complex pro-survival signaling. We hypothesized that targeting lipid metabolism via SREBP-1/2 inhibition (fatostatin) might alter the apoptotic phenotype and facilitate an apoptotic response driven by BH3 mimetics (ABT-263) in glioblastoma in vitro. Methods: Dynamic BH3 profiling was performed to detect apoptotic priming. The combined inhibition of SREBP-1/2 and Bcl-xL/Bcl-2 was evaluated across 2- and 3-dimensional culture models. The cell lines used included established cell lines as well as primary cultures and glioma stem-like cells. Extracellular flux analysis was used to assess metabolic effects. Changes in migration were evaluated through time-lapse analysis, scratch, and Transwell assays. Results: BH3 profiling showed that treatment with fatostatin increased Bcl-xL/Bcl-2 reliance, while ABT-263 increased Mcl-1 dependence. The combination showed potent synergy in inhibiting viability and spheroid growth, driven at least in part by enhanced caspase-dependent apoptosis. Mechanistically, fatostatin induced dose-dependent Mcl-1 downregulation, sensitizing cells to ABT-263. Dual treatment suppressed oxidative phosphorylation and impaired cell migration, while exhibiting low toxicity in non-pathological cells. Conclusions: This study indicates that combined inhibition of SREBP-1/2 and Bcl-xL/Bcl-2 represents a promising therapeutic strategy for the treatment of glioblastoma. The efficacy of this dual approach potentially lies in the downregulation of Mcl-1 induced by fatostatin and suppression of oxidative phosphorylation. Further studies are warranted.